New Heart Failure Drug Marketing Costs to Alleviate Novartis’ 2016 Profit
Novartis revealed on Tuesday that the company is boosting its expenditure on marketing a new heart failure drug called Entresto subsequent to disappointing initial sales of the medicine. This increase in expenditure might have a dampening impact on the profit of Novartis in 2016.
The Swiss company explained that this additional expenditure, coupled with decline in sales of leukemia treatment Gleevec, will result in core operating income in 2016 being equivalent to that of 2015 or slightly less than that at constant currencies. Novartis is the biggest prescription drugmaker across the world and its profit in the second quarter was slightly more than the expected level.
The company is relying on its new medications like Entresto and Cosentyx, used in the treatment for psoriasis, to compensate for the adverse impact of generic competition on sales of Gleevec. Entresto was launched in the summer of 2015, but has not been able to experience growth in its most important market of the US, while its sales in Europe are better.
The drug is considered to have enormous potential, with annual sales expectations of $5 billion or more. Its sales reached $32 million during the second quarter, during which sales of Cosentyx was $260 million. Novartis again claimed that it anticipates the sales of Entresto for the full year of 2016 to reach nearly $200 million.
The forecasts for Entresto were enhanced in May after it was strongly recommended for the treatment of heart failure under the new medical guidelines. Joe Jimenez, the Chief Executive Officer of Novartis, aims to benefit from this endorsement by assigning an additional expenditure of $200 million for marketing the medication during the second half of 2016.
The company’s decision to boost expenditure on sales representatives is being supported by industry analysts. "We see this as a necessary spend and one that should have been made earlier", said Tim Race, an analyst at Deutsche Bank.
Fashion major Michael Kors has agreed to acquire Jimmy Choo for $1.2 billion. New York-based Michael Kors will be able to diversify its portfolio by acquiring UK-based Jimmy Choo, a brand having strong sales in luxury segment.
Samsung is yet to officially unveil its next-generation flagship Galaxy Note 8 smartphone, but KGI Securities analyst Ming-Chi Kuo has already revealed some key details of the upcoming device’s dual camera setup.
Some employees of a tech firm in Wisconsin will soon be able to open doors, unlock office equipment, log into computers and even make in-house purchases with just a swipe of the hand.
The International Monetary Fund (IMF) has predicted US and UK economies will experience weaker-than-expected activity and expand more slowly this year than previously predicted.
The European Commission has confirmed that EU antitrust regulators are probing allegations of a cartel among a group of German carmakers, in an action that could result in bulky penalties for the companies.
Tesla Motors’ long-awaited Model 3 will be a “major test” for the Palo Alto-based electric car giant, according to industry analysts.